ouabain has been researched along with 2019 Novel Coronavirus Disease in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
| Bejček, J; Pavlíčková, VS; Rimpelová, S; Škubník, J | 1 |
| Bera, A; Caohuy, H; Chen, T; Eidelman, O; Liu, S; Pollard, HB; Walton, NI; Wang, TT; Yang, Q | 1 |
| Ferreira, RS; Qayed, WS; Silva, JRA | 1 |
1 review(s) available for ouabain and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Repurposing Cardiac Glycosides: Drugs for Heart Failure Surmounting Viruses.
Topics: Antiviral Agents; Cardiac Glycosides; COVID-19; Digitoxin; Digoxin; Drug Repositioning; Heart Failure; Humans; Neoplasms; Ouabain; Pandemics; SARS-CoV-2; Sodium-Potassium-Exchanging ATPase; Virus Internalization; Virus Replication | 2021 |
3 other study(ies) available for ouabain and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |
Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Cardiotonic Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Digitoxin; Digoxin; Humans; Lung; Ouabain; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vero Cells; Virus Internalization | 2021 |
In Silico Study towards Repositioning of FDA-Approved Drug Candidates for Anticoronaviral Therapy: Molecular Docking, Molecular Dynamics and Binding Free Energy Calculations.
Topics: Antiviral Agents; COVID-19; Cysteine Endopeptidases; Digitoxin; Digoxin; Drug Repositioning; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Niclosamide; Ouabain; Papain; Proscillaridin; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |